Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Late-Stage Trial of Abbott Kidney Drug Halted After Deaths

Drug Industry Daily

Oct. 22, 2012 | Vol. 11 No. 207

Late-Stage Trial of Abbott Kidney Drug Halted After Deaths

Abbott and Reata Pharmaceuticals are halting a Phase III trial of kidney disease drug bardoxolone after an unspecified number of patient deaths.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Related Articles

Pfizer Halts Phase III Trial of Lyphoma Drug After Interim Analysis Lilly Phase III Non-Hodgkin’s Lymphoma Drug Trial Halted Boehringer Ingelheim’s NSCLC Candidates Get Mixed Results Rise in Global Trial Recruitment Raises Ethics, Compliance Concerns in EU

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.